Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Apri another bounce off offering play. Got In at 2.59.
APPY - With offering this may be a good time to start postion leading up to phase 3 (or just short term to play the closing bounce) My 1.20 order did not get filled this am, thought it had a chance.
CLSN may move today news + SA article
New SA article - the-new-celsion-could-be-worth-4-a-share
http://seekingalpha.com/article/1452881-the-new-celsion-could-be-worth-4-a-share
5/22/2013 8:00NEWSCelsion Announces Issuance of Additional Patents Covering ThermoDox® Technologies
New SA article - the-new-celsion-could-be-worth-4-a-share
http://seekingalpha.com/article/1452881-the-new-celsion-could-be-worth-4-a-share
PSDV if this could get half the gains ALIM did I would be ecstatic.
article out http://seekingalpha.com/article/1446901-psivida-corporation-and-gtx-2-of-the-most-undervalued-biotechs-for-2013
See item number 1 post# 3700. Increased institutional ownership will also boost investor confidence and hopefully impact share price. I think it will take more, but this is an improvement.
15 New Institutional Holders
5,372,724 New Total Shares Held
Owner Name Date Shared Held Change (Shares) Change(%) Value(in 1,000s)
COMMERZBANK AKTIENGESELLSCHAFT /FI 03/31/2013 1,510,100 1,510,100 New 3,639
ING GROEP NV 03/31/2013 1,500,000 1,500,000 New 3,615
JPMORGAN CHASE & CO 03/31/2013 1,370,079 1,370,079 New 3,302
SABBY MANAGEMENT, LLC 03/31/2013 251,142 251,142 New 605
JANNEY MONTGOMERY SCOTT LLC 03/31/2013 220,500 220,500 New 531
DSC ADVISORS, L.P. 03/31/2013 210,000 210,000 New 506
UBS GLOBAL ASSET MANAGEMENT AMERICAS INC 03/31/2013 109,200 109,200 New 263
PROSHARE ADVISORS LLC 03/31/2013 58,217 58,217 New 140
STONERIDGE INVESTMENT PARTNERS LLC 03/31/2013 57,048 57,048 New 137
JANE STREET HOLDING, LLC 12/31/2012 25,189 25,189 New 61
PERCEPTIVE ADVISORS LLC 03/31/2013 20,000 20,000 New 48
SG AMERICAS SECURITIES, LLC 03/31/2013 16,726 16,726 New 40
GUGGENHEIM CAPITAL LLC 03/31/2013 12,714 12,714 New 31
SAC CAPITAL ADVISORS LP 03/31/2013 11,409 11,409 New 27
BUCKINGHAM CAPITAL MANAGEMENT, INC. 03/31/2013 400 400 New 1
I am kicking my self in the ass now too... had order in in friday that did not fill
Sa article out this am
Thanks 4kids!
7th day on threshold list.
Just a matter of time with this one
cbmx on threshold list any thoughts?
Here is some good data on 2nd (now 3rd) Submission. Near 75% get approved on the 2nd trip, up from 50% in round 1. Interesting note that from 83 drugs receiving CRL's only 1 never got approved because of a manufacturing issue and eventually was suspended by the drug maker. 3rd attempt goes up to 83% approval rate.
http://www.biotech-now.org/business-and-investments/2012/03/dealing-with-rejection-the-regulatory-kind#
info credit to Paulyboy (I kept this In my message box
paulyboy Saturday, March 16, 2013 12:16:12 PM
Re: None Post # of 5344 (
Kei finds good and makes me smile. No reason 4 that
Ultimately they won't get approval but little risk at these levels. 30 percent lower on negative ad com vs 100 percent gain. If negative will slowly climb back b4 eventual crl.
If fda tbought no chance would have had a crl not extension. Look for some covering lated
Missed the lows this week, will try to grab "new" starter next week. Expect we will have some timetable next month.
I believe last big pr was a day or two before a presentation? I do not like putting too much in one stock but I find myself adding ever time it dips below 2.45
Needham Healthcare Conference 2013
April 25, 2013 02:51 PM Eastern Daylight Time Navidea Biopharmaceuticals to Present at the Needham 12th Annual Healthcare Conference
– Chief Executive Officer to Provide Business and Development Program Updates –
Needham Healthcare Conference 2013
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, President and Chief Executive Officer, will participate at the Needham 12th Annual Healthcare Conference on April 30 - May 1, 2013 at the Westin Grand Central Hotel, New York City. Dr. Pykett will provide an update of the Company and its development programs on Wednesday, May 1, 2013 at 3:40 PM EDT.
Investors and the public are invited to listen to a live webcast of Dr. Pykett’s presentation at http://wsw.com/webcast/needham58/navb/. Following the conference, the webcast will be archived for approximately 30 days.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek®, NAV4694, NAV5001 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Contacts
Navidea Biopharmaceuticals
Brent Larson, Sr. VP & CFO
(614) 822-2330
Recent Stories
offering link
http://boardvote.com/symbol/NAVB/communique/305409
should see price move back up. small offering.
If shorts cant force this below 2.45 in this market I just do not see it happening at all.
Looking to re-enter in .31 - .32 range. crl soft and just as important FDA did not request costly tests. Will take mid size position only because I am a little concerned about possible rs and although they had 50 mil in bank, dilution is still a possibility.
I was able to sell most of my shares after CRL for @ .055. I have a GTC order at .044 hoping it gets filled. Want to have a starter before Sept. Still want my 4 bagger!
I'm confused as well. Still trying to figure out the short situation. I have been buying on the dips into the 2.50s and selling in the 2.70's. I just have to be carefull not to touch my base because this has to move some time and I want to make sure I'm on the boat.
Spa + working with Ema. With offering out of the way, low float, and offering out of the way this set to move in a few weeks. Starter@ 7.25
7:01AM Durata Therapeutics announces preliminary, topline phase 3 clinical trial results for dalbavancin in the treatment of ABSSSI; DISCOVER 2 study meets primary & secondary endpoints (DRTX) 7.41 : Preliminary top-line data show that dalbavancin achieved its primary endpoint of non-inferiority (10% non-inferiority margin) at 48-72 hours after initiation of therapy, as determined by the cessation of spread of the lesion, as well as the resolution of fever. Researchers were comparing two intravenous (IV) doses of dalbavancin given one week apart with twice-daily vancomycin doses for 14 days. Patients randomized to the vancomycin regimen had an option to switch to oral linezolid after three days of vancomycin treatment. In addition, the trial assessed as a secondary outcome measure the non-inferiority of clinical response at the end of treatment in clinically evaluable patients. Dalbavancin also achieved this secondary endpoint.
The DISCOVER 2 study was conducted pursuant to a special protocol agreement (SPA) with the U.S. Food and Drug Administration (FDA) based on the FDA's Draft Guidance for Developing Drugs for Treatment of ABSSSI. The protocol for the trial was also designed based on scientific advice provided by the European Medicines Agency (EMA).
The most commonly reported adverse events for dalbavancin in this trial were nausea, diarrhea, vomiting, pruritus and headache. Discontinuations due to treatment emergent adverse events were 2.4% and 1.9% for dalbavancin and vancomycin/linezolid, respectively. This adverse event profile is consistent with results from prior Phase 3 studies and DISCOVER 1. Additional analyses of the data are ongoing.
PRESS RELEASE: Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference
Navidea Biopharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference
Chief Executive Officer to Provide Business and Development Program Updates DUBLIN, Ohio--(BUSINESS WIRE)--April 01, 2013--
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Mark Pykett, Navidea's President and Chief Executive Officer, will participate at the Future Leaders in the Biotech Industry Conference on April 5, 2013 at the Millennium Broadway Hotel & Conference Center, New York, NY. Dr. Pykett will provide an update of the Company and its development programs at 9:30 AM EDT.
Investors and the public are invited to listen to a live webcast of Dr. Pykett's presentation at http://www.media-server.com/m/p/exttmn6v. Following the conference, the webcast will be archived for approximately 30 days.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms -- Lymphoseek(R) , NAV4694, NAV5001 and RIGScan(TM) -- to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
CONTACT: Navidea Biopharmaceuticals
Brent Larson, 614-822-2330
Sr. VP & CFO
Order free Annual Report for Navidea Biopharmaceuticals, Inc.
Visit http://djnweurope.ar.wilink.com/?ticker=US63937X1037 or call +44 (0)208 391 6028
(END) Dow Jones Newswires
04-01-13 1605ET
I took another poster's sage advice and reviewed all dd to calm my nerves a little since I held almost all my shares today. That an a nice toasted lager did the trick. Approval 8 am pr.
Hopefully this works out better than the last pdufa play that announced the following day nriff (no comparison with APPA). If they hold to pattern will be 8 am PR which is when they seem to release their prs. CC late morning?
$heff thought would be right out after the bell with approval
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=86183980
hope LTG's prediction comes true with announcement at 630 ...
Yeah same company that put out pr after fda announced approval and prevented any movement. Guess they are a little slow.
Funny FDA still sends confirmation to company via fax on PDFUA date
Yes im guessing tonite with cc 10 am
I would have been more concerned if this did not drop b4 announcement